Autolus Therapeutics PLC To Discuss the ASH data Transcript
Hello, ladies and gentlemen. I am pleased to welcome to the Autolus Therapeutics ASH 2021 Investor Conference Call. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Dr. Lucinda Crabtree, VP Business Strategy and Planning at Autolus. Please go ahead.
Thank you. Good morning or good afternoon, everyone, and thank you for joining us and taking part in today's call covering the data we have presented over the weekend at the American Society of Hematology or ASH Conference being held in Atlanta.
I'm Lucinda Crabtree, VP Business Strategy and Planning, and I'm joined today by Dr. Christian Itin, our CEO; Dr. Edgar Braendle, our Chief Development Officer; Dr. Wolfram Brugger, our Chief -- our Head of Clinical Development; Dr. Martin Pule, our Chief Scientific Officer; and Andrew Oakley, our CFO.
Before I pass you to Christian for his introduction and opening remarks, I'd
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |